Transgenic mice and organoid models, such as three-dimensional tumoroid cultures, have emerged as powerful tools for investigating cancer development and targeted therapies. Yet, the extent to which these preclinical models recapitulate the cellular identity of heterogeneous malignancies, like neuroblastoma (NB), remains to be validated. Here, we characterized the transcriptional landscape of TH-MYCN tumors by single-cell RNA sequencing (scRNA-seq) and developed ex vivo tumoroids. Integrated analysis with murine fetal adrenal samples confirmed that both TH-MYCN tumors and tumoroids closely mirror the cellular profiles of normal embryonic sympathoblasts and chromaffin cells. Comprehensive comparison between tumors from NB patients and TH-MYCN mice demonstrated similarities in adrenergic tumor cell composition. Ex vivo tumoroid cultures displayed histological resemblance and shared transcriptional profiles with the originating TH-MYCN tumors and human NB. Importantly, subpopulations within tumoroids exhibited gene expression associated with poor NB patient survival. Notably, recurrent observations of a low-proliferative chromaffin phenotype connected to the highly proliferative sympathetic phenotype suggested that pushing sympathoblasts into a chromaffin-like state may offer an interesting therapeutic strategy for NB. Together, this study not only deepens our understanding of a widely used transgenic mouse NB model but also introduces an ex vivo model that maintains critical adrenergic cell state identity, thereby enhancing its translational potential for NB research.

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-24-1507DOI Listing

Publication Analysis

Top Keywords

th-mycn tumors
12
preclinical models
8
adrenergic cell
8
cell state
8
tumoroid cultures
8
comparative single-cell
4
single-cell transcriptomics
4
transcriptomics human
4
human neuroblastoma
4
neuroblastoma preclinical
4

Similar Publications

Transgenic mice and organoid models, such as three-dimensional tumoroid cultures, have emerged as powerful tools for investigating cancer development and targeted therapies. Yet, the extent to which these preclinical models recapitulate the cellular identity of heterogeneous malignancies, like neuroblastoma (NB), remains to be validated. Here, we characterized the transcriptional landscape of TH-MYCN tumors by single-cell RNA sequencing (scRNA-seq) and developed ex vivo tumoroids.

View Article and Find Full Text PDF
Article Synopsis
  • Checkpoint immunotherapy struggles against non-immunogenic tumors like neuroblastoma due to low MHC class I expression and neoantigen burden, but inhibiting ERAP1 can enhance anti-tumor immune responses.
  • A novel strategy combining genetic knockout of ERAP1 with the HDAC inhibitor entinostat was developed, leading to increased immunogenicity and making neuroblastoma more responsive to PD-1 therapy.
  • Experimental methods included CRISPR/Cas9 gene editing, flow cytometry, and mass spectrometry to demonstrate that ERAP1 inhibition improves immune cell activity and increases MHC class I and PD-L1 expression in neuroblastoma cells, ultimately slowing tumor growth.
View Article and Find Full Text PDF
Article Synopsis
  • - MYCN amplification is linked to poor outcomes in childhood neuroblastoma and the study investigates the signaling dependencies associated with it through genetic manipulation in mice.
  • - A mutation in the RNF121 gene was found to result in decreased tumor formation, with RNF121 playing a crucial role in enhancing MYCN protein stability and contributing to tumor growth.
  • - Elevated RNF121 levels correlate with poor prognosis in neuroblastoma and laryngeal cancer, suggesting it as a potential target for new cancer therapies.
View Article and Find Full Text PDF
Article Synopsis
  • About 50% of neuroblastomas with poor prognosis are linked to the over-expression of the MYCN protein, and previous research has shown that targeting PRMT5 leads to cell death in these cases.
  • The study evaluates GSK3203591, a new PRMT5 inhibitor, showing that it inhibits MYCN-dependent growth and triggers changes in gene expression and mRNA splicing in MNA neuroblastoma cells, particularly affecting glutamine metabolism.
  • In tests on mice, the related compound GSK3326593 demonstrated increased survival, confirming that both drugs exploit PRMT5's role in splicing and regulation of metabolic pathways in MYCN-amplified neuroblastomas.
View Article and Find Full Text PDF

Oncogene-driven expression and activation of receptor tyrosine kinases promotes tumorigenesis and contributes to drug resistance. Increased expression of the kinases discoidin domain receptor 2 (DDR2), RET Proto-Oncogene (RET), Platelet Derived Growth Factor Receptor Alpha (PDGFRA), KIT Proto-Oncogene (KIT), MET Proto-Oncogene (MET), and anaplastic lymphoma kinase (ALK) independently correlate with decreased overall survival and event free survival of pediatric neuroblastoma. The multikinase inhibitor sitravatinib targets DDR2, RET, PDGFRA, KIT, and MET with low nanomolar activity and we therefore tested its efficacy against orthotopic and syngeneic tumor models.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!